Tenax Therapeutics (TENX) Other Accumulated Expenses (2013 - 2024)

Tenax Therapeutics has disclosed Other Accumulated Expenses across 12 years of filings, most recently posting $105823.0 for Q3 2024.

• Other Accumulated Expenses for Q3 2024 came in at $105823.0, down 56.9% year-over-year; the trailing twelve-month figure through Sep 2024 was $105823.0 (down 56.9% YoY), and the FY2023 annual result was $236878.0, down 3.47% from the prior year.
• Other Accumulated Expenses came in at $105823.0 for Q3 2024 at Tenax Therapeutics, down from $160581.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $503023.0 in Q1 2020 to a low of $84595.0 in Q1 2021.
• The 5-year median for Other Accumulated Expenses is $238206.0 (2022), against an average of $223434.9.
• Across the five-year window, Other Accumulated Expenses plunged 86.03% in 2020 and soared 208.98% in 2022, its largest moves.
• Tenax Therapeutics' Other Accumulated Expenses stood at $319608.0 in 2020, then slumped by 62.96% to $118372.0 in 2021, then surged by 107.3% to $245391.0 in 2022, then dropped by 3.47% to $236878.0 in 2023, then tumbled by 55.33% to $105823.0 in 2024.
• The last three Other Accumulated Expenses figures came in at $105823.0 (Q3 2024), $160581.0 (Q2 2024), and $253517.0 (Q1 2024), per Business Quant data.